FIELD: biotechnology.
SUBSTANCE: presented are an application of an antibody to PD-1 in combination with famitinib for producing a medicinal product for treating tumours; a method for alleviating the adverse reaction caused by the antibody to PD-1 or an antigen-binding fragment thereof, including the administration of famitinib or a pharmacologically acceptable salt thereof in combination with the antibody to PD-1; a method for reducing the dose of the antibody to PD-11 or an antigen-binding fragment thereof or a dose of famitinib or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical kit for treating a tumour or a cancer, containing famitinib or a pharmaceutically acceptable salt thereof and the antibody to PD-1.
EFFECT: group of inventions allows for effective application of combinations of the above antibody with famitinib for treating cancerous tumours and alleviating the side reaction in the form of a reactive capillary hyperplasia, which may occur when the antibody to PD-1 is used separately.
23 cl, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS | 2017 |
|
RU2762746C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
